{"name":"CStone Pharmaceuticals","slug":"cstone","ticker":"2616.HK","exchange":"HKEX","domain":"cstonepharma.com","description":"CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with he","hq":"Suzhou, China","founded":2015,"employees":"136","ceo":"Frank Jiang, M.D., Ph.D.","sector":"Oncology / Immunotherapy","stockPrice":8.15,"stockChange":0.28,"stockChangePercent":3.56,"marketCap":"$1.9B","metrics":{"revenue":39731620.88096416,"revenueGrowth":43.8,"grossMargin":19,"rdSpend":0,"netIncome":-64406276.81436416,"cash":141853628.36812416,"dividendYield":0,"peRatio":-44.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"CS1001 patent cliff ($1.2B at risk)","drug":"CS1001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CS1001 monoclonal antibody","genericName":"CS1001 monoclonal antibody","slug":"cs1001-monoclonal-antibody","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CS1001+ Fluorouracil+Cisplatin","genericName":"CS1001+ Fluorouracil+Cisplatin","slug":"cs1001-fluorouracil-cisplatin","indication":"Gastric or gastroesophageal junction cancer","status":"phase_3"},{"name":"Placebo+ Fluorouracil+Cisplatin","genericName":"Placebo+ Fluorouracil+Cisplatin","slug":"placebo-fluorouracil-cisplatin","indication":"Gastric or gastroesophageal junction cancer (likely indication based on CStone pipeline)","status":"phase_3"}]}],"pipeline":[{"name":"CS1001 monoclonal antibody","genericName":"CS1001 monoclonal antibody","slug":"cs1001-monoclonal-antibody","phase":"phase_3","mechanism":"CS1001 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"CS1001+ Fluorouracil+Cisplatin","genericName":"CS1001+ Fluorouracil+Cisplatin","slug":"cs1001-fluorouracil-cisplatin","phase":"phase_3","mechanism":"CS1001 is a PD-L1 inhibitor that blocks immune checkpoint signaling, combined with fluorouracil and cisplatin chemotherapy to enhance anti-tumor immunity and direct cytotoxic effects.","indications":["Gastric or gastroesophageal junction cancer","Esophageal squamous cell carcinoma"],"catalyst":""},{"name":"Placebo+ Fluorouracil+Cisplatin","genericName":"Placebo+ Fluorouracil+Cisplatin","slug":"placebo-fluorouracil-cisplatin","phase":"phase_3","mechanism":"This combination uses fluorouracil and cisplatin chemotherapy agents to inhibit DNA synthesis and induce cancer cell death, with placebo as a control arm in the trial design.","indications":["Gastric or gastroesophageal junction cancer (likely indication based on CStone pipeline)"],"catalyst":""}],"recentEvents":[{"date":"2024-06-28","type":"regulatory","headline":"CStone Pharmaceuticals Announces Acceptance of NDA for CS1001 in China","summary":"CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for CS1001, a PD-1 inhibitor, in China.","drugName":"CS1001","sentiment":"positive"},{"date":"2023-12-29","type":"earnings","headline":"CStone Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"CStone Pharmaceuticals reported its third quarter 2023 financial results, with revenue of $143.8 million and a net loss of $143.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"CStone Pharmaceuticals Enters into Licensing Agreement with Pfizer","summary":"CStone Pharmaceuticals announced that it has entered into a licensing agreement with Pfizer for the development and commercialization of CS1001 in certain territories.","drugName":"CS1001","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPS1Z0bXBDUkcxejI3Q2szaWR2VGoyaGdSSDYwSnVfM0RHNC1nYzNRM2NwS0NJZnIyNUd3aE0wLVc0aVY2TkFXdDRSVVpVS2EzdDZEczNPSXh1b3RicEtiYnRjMmgxbEJkcGFLRzV3UF9DTy1vcnJhSFlCRWVuSEpqM1gta3h3TlM5bVc1N0dDQXVJNThMZ0c0RVRGMFByRFNoV1JjQTluMFdkZ09uTGJXSFVzZTBEVm1nN292QWZPdEttNFNYejREZA?oc=5","date":"2026-03-29","type":"pipeline","source":"Smartkarma","summary":"CStone Pharma (2616 HK): 2025 Seen Off Well, 2026 Would Be Crucial. A Possible Turnaround On Cards? - Smartkarma","headline":"CStone Pharma (2616 HK): 2025 Seen Off Well, 2026 Would Be Crucial. A Possible Turnaround On Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPcmE5MjR3c25NVFlPS0NTOHZsZlB0cEtjOVU0dGJBS3lYVGQzLTlkYjI5ZHVLUTc5NmI4cXhzZ1lrdVhYMm5KTGRrZXExMWtXTmRyZ0pfa0VGMFJHN3lBbm5Db25aSy02NHBfTzl1cnJ3UnVWTmt5eXc1blAtRWJtZFBIa0xKYVR0Rnh4Q3hiLXJRbmpxTVRhQnoyYjJoQ0sxd2JKM2NHWm11YUkwejYwUG13dllQM1k?oc=5","date":"2026-03-29","type":"earnings","source":"Moomoo","summary":"Earnings Update: CStone Pharmaceuticals (HKG:2616) Just Reported And Analysts Are Trimming Their Forecasts - Moomoo","headline":"Earnings Update: CStone Pharmaceuticals (HKG:2616) Just Reported And Analysts Are Trimming Their Forecasts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPTU4xXy1iV3NuS1ZCRDEyS25RaDNTYnh5YmFhZkZGbTIyWUdZS3ZENkstNlJxWkU2MTBpUjVsSWhUN09GdWFsekZoWVo5RzdtQm85M3lVUUs0MTZRcXFZbi1tRVZkRjlObURzWnRQa1dDRnNVV0E3UHpRQzRDTVpITTd3OUFYRjI5SUp3cjEwaGM4bnZNRUpZc2kxa0lrUm5mWnNkWjVn?oc=5","date":"2026-03-11","type":"pipeline","source":"The Standard (HK)","summary":"Softbank offloads SenseTime stake, pharma eyes $400m - The Standard (HK)","headline":"Softbank offloads SenseTime stake, pharma eyes $400m - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSnZsY0xnVGhXYXlweXFHYmFCaHNWY2UtU2ZHV29EQWttYzRpRlV6UndpNmJRa2ZyaG81eUFfajRQNmFRVWdqRVRZZmUwZEVxU0ZUMDQ0LWRVQ3VmZ2tzYkhDOXNwZlBYYkkzcklOMWV2TngyWE1WSC1OcWhaaDZSeTFQNmxvOEdLc1VfeFhTMU95M1l6SmtMOTFpMy14YUYxS0lPTzlxeXFYdnh6R2lTWXJZankzR1dfMk5kV1ROUHIxQQ?oc=5","date":"2026-02-22","type":"pipeline","source":"Smartkarma","summary":"APAC Healthcare Weekly (February 22) – Sino Bio, Hansoh Pharma, Daiichi Sankyo, Ono, ABL Bio, CSL - Smartkarma","headline":"APAC Healthcare Weekly (February 22) – Sino Bio, Hansoh Pharma, Daiichi Sankyo, Ono, ABL Bio, CSL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNRFc0WVd3TnY0RXFjQmEzWnNOejNWOXV5MXVIYTdRc0NuS1R3ZHItVlAwYmR2UmhWcnB6RTZ5aVNPa0d2bk8yZ2lOWUdZMGNyU2tmMHVkWTVVc1Rvcm8yWnpPOWlQa1lwNldnNE5SbHV3T0s5WUxJc0owWHBBX0l1OHF0Q2FhOHpxTVlxZndVdVVuRDA?oc=5","date":"2024-09-19","type":"pipeline","source":"thebambooworks.com","summary":"CSPC Pharma taps R&D superstar in quest for new breakout drugs - thebambooworks.com","headline":"CSPC Pharma taps R&D superstar in quest for new breakout drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9iZG1NaEFwUmtFZF8tQnAzdzZlU3hUei1mbDdGS1l2MmVBMDk0bVUwbEdnMlRiemtrUnNvOEhBRjFmQzB1SmF1bDBXTUt3WVhfTERTUHp3?oc=5","date":"2024-05-31","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNZUlpRndvcFdXRTM2TlJwdW1qTUhnb0MwMFo0cElsbEdWcU1KMzBxQ0hFS0NtUGhqZl9ORF9fN1RXMGFXVjMxZHFqcnhUSDhxVXVIVHJJcHF6VzFwLXc2Ym9tTDZOdjhDQzZZb3g4Wk1hT1NfUmxIU3BxZUgxak94NS1WYmtzbDhGTkVRY3BEc2tSVElLZ1NJcHhwLUdHWWk1UGVFQVp4SEI0Y2lQVmEzdw?oc=5","date":"2023-06-27","type":"regulatory","source":"thebambooworks.com","summary":"FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer - thebambooworks.com","headline":"FAST NEWS: CStone drug approved for treatment of advanced non-small cell lung cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5SdFd0Zy1SWDQtOFk5UG1BN2N5VXhYT21Rb2lFUDFIUmhOX08yM19jaXc1VUs3M2ZFM1ZtOHNacTc5SUktOHB5M2xXVFU5RWVfeEt2cGN3?oc=5","date":"2021-02-15","type":"pipeline","source":"Yahoo Finance Singapore","summary":"InnoCare Pharma Limited (9969.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"InnoCare Pharma Limited (9969.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBqdzVaVktZWFhHR2tmZ1VCcldib05Nc2c5TjRieEVpY2M0a0FBR2daRkZhSGtEeEswUGc3LW1Ockg3S1dFMl9haDhfbU9NQkRNLUVtdmNR?oc=5","date":"2019-11-04","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Ascentage Pharma Group International (6855.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Ascentage Pharma Group International (6855.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE85ZEo4YjdueXphX2RsUjRodmhWaGxQVG56VlN3MGJhZ0J0YTg1Z3pJT21QeU5NeTcxRlZhT0ZGWTVITGUxM29HT0ItZjdEV2Rnbm1BY2ZxS3JPUQ?oc=5","date":"2019-02-25","type":"pipeline","source":"TradingView","summary":"2616 Stock Price and Chart — HKEX:2616 - TradingView","headline":"2616 Stock Price and Chart — HKEX:2616","sentiment":"neutral"}],"patents":[{"drugName":"CS1001","drugSlug":"pembrolizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Oncology","Immunotherapy"],"financials":{"source":"yahoo_finance","revenue":39731619.70191,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":39731619.70191},{"period":"2024-12-31","value":60014593.652849995},{"period":"2023-12-31","value":68361854.96034},{"period":"2022-12-31","value":70944130.95251}],"grossProfit":7552873.56719,"grossProfitHistory":[{"period":"2025-12-31","value":7552873.56719},{"period":"2024-12-31","value":35394321.59258},{"period":"2023-12-31","value":44847535.70215},{"period":"2022-12-31","value":41027842.36906}],"rdSpend":45910010.882079996,"rdSpendHistory":[{"period":"2025-12-31","value":45910010.882079996},{"period":"2024-12-31","value":19845987.00289},{"period":"2023-12-31","value":77787950.82423},{"period":"2022-12-31","value":90516282.62674}],"sgaSpend":16681847.78276,"operatingIncome":-61531152.066149995,"operatingIncomeHistory":[{"period":"2025-12-31","value":-61531152.066149995},{"period":"2024-12-31","value":-13513729.25484},{"period":"2023-12-31","value":-85458582.42565},{"period":"2022-12-31","value":-133100034.34168999}],"netIncome":-64406275.635309994,"netIncomeHistory":[{"period":"2025-12-31","value":-64406275.635309994},{"period":"2024-12-31","value":-13442249.09639},{"period":"2023-12-31","value":-54123596.92418},{"period":"2022-12-31","value":-133038281.38006}],"eps":-0.31,"epsHistory":[{"period":"2025-12-31","value":-0.31},{"period":"2024-12-31","value":-0.07},{"period":"2023-12-31","value":-0.29},{"period":"2022-12-31","value":-0.77}],"cash":111081492.66723,"cashHistory":[{"period":"2025-12-31","value":111081492.66723},{"period":"2024-12-31","value":57174841.70849},{"period":"2023-12-31","value":146891136.08767},{"period":"2022-12-31","value":82339836.79067999}],"totalAssets":200198680.15136,"totalLiabilities":109298173.25023,"totalDebt":51365052.33509,"equity":90900506.90112999,"operatingCashflow":-48303932.97219,"operatingCashflowHistory":[{"period":"2025-12-31","value":-48303932.97219},{"period":"2024-12-31","value":-44688068.627009995},{"period":"2023-12-31","value":-86784723.59211},{"period":"2022-12-31","value":-90012384.35511}],"capex":-9586741.99319,"capexHistory":[{"period":"2023-12-31","value":-9586741.99319},{"period":"2022-12-31","value":-15006559.20317},{"period":"2021-12-31","value":-21979927.65072}],"freeCashflow":-48303932.97219,"dividendsPaid":null,"buybacks":0,"employees":136,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.15,"previousClose":7.87,"fiftyTwoWeekHigh":13.15,"fiftyTwoWeekLow":2.75,"fiftyTwoWeekRange":"2.75 - 13.15","fiftyDayAverage":8.48,"twoHundredDayAverage":7.29,"beta":0.25,"enterpriseValue":1679953644.1443224,"forwardPE":-44.9,"priceToBook":16.92,"priceToSales":48.32,"enterpriseToRevenue":42.28,"enterpriseToEbitda":-28.23,"pegRatio":0,"ebitda":-59519540.64552832,"ebitdaMargin":-149.8,"freeCashflow":-37001759.14242448,"operatingCashflow":-48303934.151244156,"totalDebt":51365051.15603584,"debtToEquity":56.5,"currentRatio":2.18,"returnOnAssets":-18.9,"returnOnEquity":-89.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":14.4,"targetHighPrice":20.37,"targetLowPrice":9.62,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":22.1,"institutionHeldPercent":15.4,"sharesOutstanding":1598199929,"floatShares":1102936049,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.36,"epsForward":-0.18,"revenuePerShare":0.19,"bookValue":0.48,"officers":[{"age":61,"name":"Dr. Jianxin  Yang M.D., Ph.D.","title":"CEO, President of R&D and Executive Director"},{"age":34,"name":"Ms. Weicong  Ni","title":"CFO & Company Secretary"},{"age":46,"name":"Ms. Ying Hua  Zhang","title":"Senior VP & Chief Operating Officer"},{"age":50,"name":"Mr. Michael J.  Choi M.B.A.","title":"Chief Business & Strategy Officer"},{"age":47,"name":"Dr. Yujuan  La Ph.D.","title":"Senior Vice President of Product Development"},{"age":49,"name":"Dr. Qingmei  Shi M.D., Ph.D.","title":"Senior VP & Chief Medical Officer"},{"age":41,"name":"Dr. Qinzhou  Qi Ph.D.","title":"VP and Head of R&D Management & Chief of Staff to the CEO"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.cstonepharma.com","phone":"86 512 8718 6550"}}